The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Genomic analysis of circulating cell-free DNA (cfDNA) to investigate mechanisms of primary and acquired resistance to enzalutamide (ENZ) in metastatic castration-resistant prostate cancer (mCRPC).
 
Arun Azad
Honoraria - Astellas Pharma; Janssen
Research Funding - Astellas Pharma
 
Alexander Wyatt
No Relationships to Disclose
 
Stanislav Volik
No Relationships to Disclose
 
Anne Haegert
No Relationships to Disclose
 
Fan Mo
No Relationships to Disclose
 
Stephane Le Bihan
No Relationships to Disclose
 
Robert H Bell
No Relationships to Disclose
 
Shawn A Anderson
No Relationships to Disclose
 
Brian McConeghy
No Relationships to Disclose
 
Robert Shukin
No Relationships to Disclose
 
Martin Edwin Gleave
Leadership - Oncogenex
Stock and Other Ownership Interests - Oncogenex
Consulting or Advisory Role - AstraZeneca; Sanofi
Research Funding - AstraZeneca; Oncogenex; Pfizer; Sanofi
 
Colin Collins
No Relationships to Disclose
 
Kim N. Chi
Honoraria - Astellas Pharma; Janssen; Sanofi
Consulting or Advisory Role - Amgen; Astellas Pharma; Bayer; ESSA; Janssen; Lilly/ImClone; Sanofi; Takeda
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Bayer (Inst); Exelixis (Inst); Janssen (Inst); Novartis (Inst); Oncogenex (Inst); Sanofi (Inst); Teva (Inst); Tokai Pharmaceuticals (Inst)